DIAGNOSTIC DELAY AND MISDIAGNOSIS IN INTERSTITIAL LUNG DISEASE
Main Article Content
Keywords
Diagnostic delay, Misdiagnosis, interstitial lung disease
Abstract
Background: Interstitial lung diseases (ILD) refers to a group of unrelated diseases with both known and unknown causative agents. Interstitial lung disease patients frequently experience delays in diagnosis.
Objective: The aim of the current study was to determine the diagnostic delay and misdiagnosis in interstitial lung disease.
Methodology: The current cross sectional study was carried out at the Department of medicine, Bolan medical college/ Bolan medical complex hospital Quetta from July 2023 to December 2023 after taking permission from the ethical committee of the institute. The sample size was determined by the formula (2p (1-p)/d2). Only verified incidents of ILD were included. SPSS version 24 was employed for the statistical analysis.
Results: A total of 74 individuals participated in this study out of which 56(75.6%) were female and 18 (24.3%) were male. Majority of patients were in the age group from 50 to 65 years old. lower socio-economic group had primary identification of asthma 30(40.5%) and 30(40.5%) participants were on Anti-tuberculosis treatment. The diagnosis was delayed by a mean of (18.43 ± 11.232). Males experienced a greater delay in diagnosis than females did. Maximum delay in the diagnosis was noted in the individual’s age 50 to 65 years old.
Conclusion: It was concluded that interstitial lung disease individuals are diagnosed after a significant delay and provide significant diagnostic challenges for basic and secondary care.
References
2. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198:e44-e68.
3. Martinez FJ, Chisholm A, Collard HR, Flaherty KR, Myers J, Raghu G, et al. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respir Med 2017; 5:61-71.
4. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002; 19:275-83.
5. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199-203.
6. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.Am J Respir Crit Care Med 2011;183:788-824.
7. Oldham JM, Noth I. Idiopathic pulmonary fibrosis: early detection and referral. Respir Med 2014; 108:819–29.
8. Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients. Chron Resp Dis 2011;8:225–31.
9. Cosgrove GP, Bianchi P, Danese S, Lederer DJ. Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulm Med 2018; 18:9-13.
10. Bonella F, Wijsenbeek M, Molina-Molina M, Duck A,Mele R, Geissler K, et al. European IPF patient charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J 2016; 47:597–606.
11. Jones RC, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med 2014; 2:267-76.
12. Martinez FJ, Chisholm A, Collard HR, Flaherty KR, Myers J, Raghu G, et al. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respir Med 2017; 5:61-71.
13. Antoniou KM, Symvoulakis EK, Margaritopoulos GA, Lionis C, Wells AU. Early diagnosis of IPF: time for a primary-care case-finding initiative? Lancet Respir Med 2014; 2:-1.
14. Crisan-Dabija R., Mihaescu T. Analysis of possible diagnostic errors—A proposed formula to improve the management of respiratory patients; Proceedings of the E-Health and Bioengineering Conference (EHB); Sinaia, Romania. 22–24 June 2017; pp. 486–489
15. Schoenheit G., Becattelli I., Cohen A.H. Living with idiopathic pulmonary fibrosis: An in-depth qualitative survey of European patients. Chron. Respir. Dis. 2011; 8:225–231.
16. Mujeeb Rahman KK, Samaria JK.Diagnostic delay and misdiagnosis in interstitial lung disease (ILD) at primary health care level. Eue Resp J 2016; 48:1-5.
17.Pritchard D, Adengunsoye A, Lafond E, Pugashetti JV, digeronimo R, Boctor N et al. Diagnostic test interpretation and referral delay in patients with interstitial lung disease. Respir Res 2019; 20:253-8
18. Bahtouee M, Saberifard J, Javadi H, Nabipour I, Raeisi A, Assadi M et al. 99mTc-MIBI Lung cintigraphy in the Assessment of Pulmonary Involvement in Interstitial Lung Disease and its Comparison with Pulmonary Function Tests and High-Resolution Computed Tomography: A Preliminary Study. Medicine (Baltimore) 2015; 94:e2082
19.Cobo-Ibáñez T, López-Longo FJ, Joven B, Carreira PE, Muñoz-Fernández S, Maldonado-Romero V, et al. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. Clin Rheumatol 2019; 38:803-15
21. Hagmeyer L, Randerath W. Smoking-related interstitial lung disease. Dtsch Arztebl Int 2015; 112:43-50
22.Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin 2019; 35:2015-24